Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

McClure's equity compensation includes service-based vesting and performance awards tied to 2029 financial and stock-price metrics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass.--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine (“Katie”) McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.

Ms. McClure brings more than 20 years of experience in transforming innovative medical technologies into sustainable commercial growth through strategic leadership, talent development, physician engagement, and enterprise partnerships. Ms. McClure joins Myomo from Inspire Medical Systems (“Inspire” NASDAQ:INSP), a fast-growing medical technology company for whom she was employed since 2018. During her tenure at Inspire, revenues grew from approximately $50 million to nearly $1 billion and, in the territories under her leadership, increased from $2 million to $150 million. Prior to Inspire, Ms. McClure held senior medical device sales roles at Medtronic, Tobii Dynavox and Johnson & Johnson.

“We are excited for Katie to join us as we enter our next phase of growth,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. "Her experience building commercial teams, expanding market access, and scaling clinical networks is directly relevant to our strategic plan.”

“My passion is in developing commercial enterprises. The MyoPro is a life-changing product for people suffering from upper-extremity impairment. I’m confident we can build a sustainable nationwide eco-system of orthotics and prosthetics providers, therapists and other healthcare professionals to expand market awareness of and access to the MyoPro,” said Ms. McClure.

Micah Mitchell, the Company’s former Chief Commercial Officer, will remain with the Company until December 23, 2026 in order to facilitate a smooth transition. Mr. Gudonis said, “I would like to thank Micah for his significant contributions to the Company. Micah was instrumental in building our commercial organization to support the creation of our direct provider business, which now represents approximately 70% of our annual revenues. His leadership in growing the company’s revenues from less than $2 million to over $40 million is greatly appreciated, and we wish him continued success in his future endeavors.”

In connection with Ms. McClure’s acceptance of appointment with the Company, effective on the first day of Ms. McClure’s employment, Ms. McClure was granted a time-based equity award, consisting of restricted stock units (“RSU’s”) covering 275,000 shares of the Company’s common stock, of which 100,000 shares will vest on the six (6) month anniversary of her employment start date, 25,000 shares on the first anniversary of her employment start date, 125,000 shares on the second anniversary of her employment start date, and the remainder on the third anniversary of her employment start date, subject to her continued service through each applicable vesting date.

In addition, Ms. McClure was granted a performance-based equity award, consisting of performance-based RSU’s covering 225,000 shares of the Company’s common stock at target. With respect to vesting, 50% of the award will vest based on achievement of certain financial metrics for the year ended December 31, 2029, based on an operating plan approved by the Compensation Committee. The remaining 50% will vest based on the Company’s stock price performance in the fourth quarter of 2029 compared to the fourth quarter of 2026 relative to a group of peer companies. Based on performance against these metrics, Ms. McClure may earn between 0% and 150% of the target amount, up to a maximum of 337,500 shares.

The RSU’s are subject to the terms and conditions of the RSU award agreements covering the grants.

These equity awards were approved by the Compensation Committee of the Board of Directors of the Company as an inducement material to Ms. McClure’s entering into employment with the Company in reliance on the employment inducement exception under Section 711 of the NYSE American Company Guide.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations for building a sustainable ecosystem of orthotics and prosthetics providers, therapists and other healthcare professionals, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• our ability to obtain sufficient reimbursement from third-party payers for our products;
• our dependence on external sources for the financing of our operations;
• our ability to scale the business to achieve positive cash flow from operations;
• our revenue concentration with patients who carry Medicare Part B;
• our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
• our marketing and commercialization efforts;
• our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
• our expectations as to our product development programs, including improving our existing products and developing new products;
• our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
• our expectations as to our clinical research program and clinical results;
• our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
• our ability to gain and maintain regulatory approvals;
• our ability to compete and succeed in a highly competitive and evolving industry; and
• general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261012506126/en/

Myomo
ir@myomo.com

Alliance Advisors IR
Vivian Cervantes
vcervantess@allianceadvisors.com
973-873-7724

Source: Myomo, Inc.

Key Terms

restricted stock units financial

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

emg medical

Electromyography (EMG) is a diagnostic test that measures the tiny electrical signals produced by muscles when they contract, using sensors placed on the skin or small needles inserted into the muscle. For investors, EMG results matter when they relate to medical devices, drugs, or therapies because clear improvements or safety signals can indicate clinical benefit and drive regulatory approval, market adoption, and potential revenue—similar to an electrician testing wiring to confirm a building is safe and functional.

orthosis medical

A orthosis is a medical device—such as a brace, splint, shoe insert or support—worn outside the body to support, align, protect or improve the function of a limb or the spine. For investors it signals a part of the healthcare equipment market tied to durable product sales, reimbursement rules, regulatory approvals and ongoing demand from hospitals, clinics and patients; changes in coverage, technology or aging demographics can affect revenue and profit outlooks for companies that make or supply them.